Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Lately, Pfizer (NYSE: PFE) ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Shares of Pfizer (NYSE: PFE) fell by 1.42% over the past month, bringing its year-to-date loss to 11.67%. Over the past year, the stock has fallen by more than 20%. Recently, the FDA announced it will ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Pfizer CEO Dr. Albert Bourla speaks to CNN’s Meg Tirrell about pushing past vaccine skepticism to work with the Trump ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...